Health Industry Watch
SEE OTHER BRANDS

Your healthcare and wellness news reporter

Health Industry Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.

Press releases published on June 3, 2025

Business Reporter: The Flex testing framework

Business Reporter: The Flex testing framework

Offering patients the best diagnostic choice based on their medical records LONDON, UNITED KINGDOM, June 3, 2025 /⁨EINPresswire.com⁩/ -- In a video published on Business Reporter, Angelo Rago, President, Luminex Division of Diasorin shares his insights on …

Bierman Autism Centers Expands Access With New Columbus Clinic Opening Fall 2025

Bierman Autism Centers Expands Access With New Columbus Clinic Opening Fall 2025

Bierman opens fourth Ohio clinic in Columbus fall 2025, expanding ABA, speech …

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today …

Fennec Announces Results of Annual Meeting

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of …

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to two new employees. Effective June 1, 2025, in connection with commencing employment, two …

DBV Technologies publie un amendement à son Document d’enregistrement universel 2024

DBV Technologies publie un amendement à son Document d’enregistrement universel 2024

Châtillon, France, le 3 juin 2025 DBV Technologies publie un amendement à son Document d’enregistrement universel 2024 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), société biopharmaceutique en …

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company …

Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

ORION OYJ LEHDISTÖTIEDOTE 3.6.2025 klo 23.30          Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa Darolutamidi on ensimmäinen ja ainoa androgeenireseptorin …

Outset Medical Appoints Renee Gaeta as Chief Financial Officer

Outset Medical Appoints Renee Gaeta as Chief Financial Officer

SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee …

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer

ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST           U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor ( …

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, …

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today …

Virtual Healthcare Market CAGR 21.41 % with Growth USD 27026.61 Million by 2033

Virtual Healthcare Market CAGR 21.41 % with Growth USD 27026.61 Million by 2033

Global Virtual Healthcare market size is anticipated to be worth USD 5724.75 M in 2025, projected to reach 27026.61 M by 2033 at a CAGR of 21.41% PUNE, INTERNATIONAL, INDIA, June 3, 2025 /⁨EINPresswire.com⁩/ -- "Virtual Healthcare Market" research …

Drug Screening Market CAGR 12.29 % with Growth USD 16814.2 Billion by 2033

Drug Screening Market CAGR 12.29 % with Growth USD 16814.2 Billion by 2033

Drug Screening market size is anticipated to be worth USD 6651.93 million in 2025 and is expected to reach 16814.2 million by 2033 at a CAGR of 12.29%. PUNE, INTERNATIONAL, INDIA, June 3, 2025 /⁨EINPresswire.com⁩/ -- "Drug Screening Market" research …

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has received …

Allotex Appoints Dirk Muehlhoff to its Board of Directors

Allotex Appoints Dirk Muehlhoff to its Board of Directors

Seasoned ophthalmic industry leader joins Allotex Board to strengthen strategic positioning and support global scale-up of its presbyopia correction platform. MILANO, ITALY, June 3, 2025 /⁨EINPresswire.com⁩/ -- Allotex group, a leader in natural tissue- …

Jushi Holdings Inc. Announces Voting Results of Annual Shareholders’ Meeting

Jushi Holdings Inc. Announces Voting Results of Annual Shareholders’ Meeting

BOCA RATON, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Corporation”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced the voting results of the annual general meeting (the “ …

Fortrea to Present at the Jefferies Global Healthcare Conference

Fortrea to Present at the Jefferies Global Healthcare Conference

DURHAM, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Interim Chief Executive Officer, Peter M. Neupert and Chief Financial Officer, Jill McConnell …

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service